ReviewAntibiotics (Basel, Switzerland)2019
Actinomycete-Derived Polyketides as a Source of Antibiotics and Lead Structures for the Development of New Antimicrobial Drugs.
Review in Antibiotics (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- NewTheScientificWorldJournal · 2025Pooled it
- Sustainable Biocatalytic Cascades: A Versatile Tool in the Synthesis of Natural Products With Therapeutic Potential.Chembiochem : a European journal of chemical biology · 2026Review
- Genome-Guided Discovery of an Antimicrobial Peptide Scaffold from an Undescribed AntarcticInternational journal of molecular sciences · 2026Article
- Engineering an IndustrialMicroorganisms · 2026Article
- Integrated GC-MS and UHPLC-HRMS/MS profiling of bioactive compounds from Streptomyces sp. BPA-6 isolated from bees-collected pollen.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Mechanistic insights and biotechnological applications of Streptomyces secondary metabolites in plant abiotic stress mitigation.World journal of microbiology & biotechnology · 2026Review
- Biodiversity and Biological Interactions of Actinobacteria Associated with Deep Sea and Intertidal Marine Invertebrates.Marine drugs · 2025Article
- Exploring the Bioactive Secondary Metabolites of Two ArgentineJournal of fungi (Basel, Switzerland) · 2025Article
- Novel endophytic actinomycetes species Streptomyces panacea of Panax sokpayensis produce antimicrobial compounds against multidrug resistant Staphylococcus aureus.Scientific reports · 2025Article
- Structural basis for intermodular communication in assembly-line polyketide biosynthesis.Nature chemical biology · 2025Article
- Antifungal Potential of Streptomyces-Derived Metabolites Against Fluconazole-Resistant Oral Candida albicans: In vitro Evaluation and Mechanistic Insights.Iranian biomedical journal · 2025Article
- Inoculum of EndophyticPlants (Basel, Switzerland) · 2025Article
- Genomic Insights and Antimicrobial Potential of NewlyMicroorganisms · 2025Article
- Bioactive polyketides from cultures of the entomopathogenic fungusRSC advances · 2025Article
- Chromosome-Level Genome Assembly and Annotation of the Highly HeterozygousJournal of fungi (Basel, Switzerland) · 2025Article
- Social wasp-associated Tsukamurella sp. strains showed promising biosynthetic and bioactive potential for discovery of novel compounds.Scientific reports · 2024Article
- Molecular docking, molecular dynamics simulations and binding free energy studies of interactions between Mycobacterium tuberculosis Pks13, PknG and bioactive constituents of extremophilic bacteria.Scientific reports · 2024Article
- Natural Products and Pharmacological Properties of Symbiotic Bacillota (Firmicutes) of Marine Macroalgae.Marine drugs · 2023Review
- Article
- Complete genome sequence ofMicrobiology resource announcements · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Actinomycetes are remarkable producers of compounds essential for human and veterinary medicine as well as for agriculture. The genomes of those microorganisms possess several sets of genes (biosynthetic gene cluster (BGC)) encoding pathways for the production of the valuable secondary metabolites. A significant proportion of the identified BGCs in actinomycetes encode pathways for the biosynthesis of polyketide compounds, nonribosomal peptides, or hybrid products resulting from the combination of both polyketide synthases (PKSs) and nonribosomal peptide synthetases (NRPSs). The potency of these molecules, in terms of bioactivity, was recognized in the 1940s, and started the "Golden Age" of antimicrobial drug discovery. Since then, several valuable polyketide drugs, such as erythromycin A, tylosin, monensin A, rifamycin, tetracyclines, amphotericin B, and many others were isolated from actinomycetes. This review covers the most relevant actinomycetes-derived polyketide drugs with antimicrobial activity, including anti-fungal agents. We provide an overview of the source of the compounds, structure of the molecules, the biosynthetic principle, bioactivity and mechanisms of action, and the current stage of development. This review emphasizes the importance of actinomycetes-derived antimicrobial polyketides and should serve as a "lexicon", not only to scientists from the Natural Products field, but also to clinicians and others interested in this topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.